Navigation Links
AMDL Signs MOU for 200 Store Distribution Arrangements for Goodnak Product Line
Date:4/30/2008

TUSTIN, Calif., April 30 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc., (JPI), the Company engages in the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products.

AMDL today announced that JPI has signed a Memorandum of Understanding (MOU) with Zhejiang HuaDu Beauty Co. Ltd. HuaDu owns more than 200 beauty stores and a beauty care training school located in Zhejiang province. The MOU creates a path for HuaDu to sell JPI's Goodnak anti-aging product and a new to-be-launched set of seven new Goodnak non-injectable anti-aging human products. These seven new Goodnak products are anticipated to be marketed during the second and third quarters of 2008.

JPI also recently held a conference in the city of Hangzhou to discuss with various beauty salon operators and regional hospitals the development of JPGREEN Anti-Aging Clinics. These clinics would be developed primarily through the conversion of existing operations into JPGREEN Anti-Aging Clinics locations. It is anticipated that a minimum of 100 JPGREEN Anti-Aging Clinics and at least 13 Hospital operated therapeutic anti-aging clinics would be developed over the next 12 months.

Mr. Gary Dreher, CEO of AMDL, noted that "our new JPGREEN Anti-Aging Clinics concept appears to be the most prudent path to developing and expanding this important area of JPI's business."

About Jade Pharmaceutical: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, JPI currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

Voice Mail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nihon LocalSoft Designs New Japanese Software for IRadimed Corporations Award-Winning MRidium MRI Infusion System
2. President Signs Elder Falls Bill Into Law
3. Phyhealth Signs Agreement with Advantica EyeCare to Provide Vision Services for Pilot HMO
4. Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
5. Breckenridge Pharmaceutical Signs Letter of Intent for Long Term Agreement With Orit Laboratories (West Caldwell, NJ)
6. New Patient Monitoring Devices Handle More Than Just Vital Signs
7. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
8. Governor Rendell Signs Bill Into Law
9. Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination
10. Pharsight Signs New Diabetes Meta-Database Customer
11. Governor Strickland Signs House Bill 125 Into Law
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Ron ... an option to senior, upper-level executives speaking at a business luncheon today, "It ... high-level executive is an asset to be fully realized and activated by the ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a ... Reward” is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible ... we returned to our cars, my sister-in-law invited us to come over before the ...
(Date:9/25/2017)... September 25, 2017 - Orlando, FL, Microsoft Ignite Conference (PRWEB) , ... ... ... Hosts, Inc . announced today that they have teamed up to deliver Netmail’s Hadron ... on-demand service from a HIPAA/HITRUST compliant Azure Cloud. Netmail will be demo-ing their Hadron ...
(Date:9/25/2017)... ... ... Ash Borers kill Ash trees in as little as 1-3 years. The signs ... by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in ... signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
(Date:9/24/2017)... & Caicos Islands, BWI (PRWEB) , ... September 25, 2017 , ... ... to announce the resort is re-opening on October 1st. And, throughout the month ... three bedroom oceanfront rentals. , Hurricane Irma and Maria have passed and damage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: